Amgen is also testing dosing as rarely as four to six shots a year. Sweeney says its two pivotal programs are fully enrolled and launch follows once treatment wraps.
Recap by typeshit. Full story at Healthcare Brew.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
Law360 reports the European patent court could limit the use of divisional patents in a fight involving Novo Nordisk and Ozempic.
Novo had asked the court to halt Lilly advertising it objected to. The judge ruled against the request on October 26, Reuters reports.
Loading…